Opinion

Video

Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL

Author(s):

Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.

Related Videos
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024..
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss their clinical practice experience using tafasitamab in relapsed/refractory DLBCL.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for tafasitamab in relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.
Related Content